TABLE 2.

Platelet parameters at end-of-therapy visit on study days 11 to 13, safety analysis population from ESTABLISH-1 and ESTABLISH-2^a

Patient group	Platelet count (cells/mm3), outcome	Data (no. [%]) for patients taking:		Relative risk (95% CId)
		200 mg tedizolid QD	600 mg linezolid BID
Received ≥1 dose of study drugb	<150,000, <LLN	27 (4.9)	58 (10.8)	0.45 (0.29–0.71)
	<112,500, <75% LLN	7 (1.3)	20 (3.7)	0.34 (0.15–0.80)
	<100,000	4 (0.7)	14 (2.6)	0.28 (0.09–0.84)
	<50,000	1 (0.2)	0 (0.0)	NA
	<20,000	0 (0.0)	0 (0.0)	NA
Received ≥1 dose of study drug and had baseline platelet count of >150,000 cells/mm3c	150,000, <LLN	16 (3.4)	31 (6.8)	0.50 (0.28–0.90)
	<112,500, <75% LLN	4 (0.9)	8 (1.8)	0.49 (0.15–1.60)
	<100,000	2 (0.4)	3 (0.7)	0.65 (0.11–3.85)
	<50,000	1 (0.2)	0 (0.0)	NA
	<20,000	0 (0.0)	0 (0.0)	NA
	≥50% decrease from baseline	4 (0.9)	7 (1.5)	0.55 (0.16–1.88)

^aPatients were randomly assigned to receive once-daily (QD) dosing of tedizolid for 6 days or twice-daily (BID) dosing of linezolid for 10 days.

^bn = 552 tedizolid and 538 linezolid.

^cn = 467 tedizolid and 453 linezolid.

^dCI, confidence interval; NA, not applicable.